Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.

Journal of neural transmission (Vienna, Austria : 1996) - 1 Jul 2002

Panisset M, Gauthier S, Moessler H, Windisch M

Abstract excerpt

UNLABELLED: Cerebrolysin (Cere) is a compound with neurotrophic activity. It has been shown to be effective in the treatment of Alzheimer's disease (AD) in earlier trials. In this multicenter, randomized, double-blind, placebo-controlled, parallel-group study, patients were injected intravenously with placebo or 30 mL Cere five days per week for four weeks. Effects on cognition and global function were evaluated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acids
Share to Cognition
Share to Depression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disability Evaluation

Share to Double-Blind Method

Share to Neuroprotective Agents

Share to Placebos

Share to Psychiatric Status Rating Scales

Source

Identifiers

PMID: 12111446
DOI: 10.1007/s007020200092

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.PMID 12111446Read ↗

Safety, tolerability and efficacy outcomes of the Investigation of Levetiracetam in Alzheimer’s Disease (ILiAD) trialSemantic proximity Read ↗

The effects of rasagiline on cerebral glucose metabolism, cognition, and tau in a double-blind, placebo-controlled Phase II clinical trial in Alzheimer’s dementiaSemantic proximity Read ↗

Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer's disease.Semantic proximity Read ↗

Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies.Semantic proximity Read ↗

Diosgenin-Rich Yam Extract Enhances Cognitive Function: A Placebo-Controlled, Randomized, Double-Blind, Crossover Study of Healthy AdultsSemantic proximity Read ↗

[ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer's disease].Semantic proximity Read ↗

Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.Semantic proximity Read ↗

Disease‐modifying therapies in Alzheimer's diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.